InflaRx Announces Positive Topline Results in Phase 1 Antiinflamatory Study

 

• MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days:
  • Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing period
  • Achieved favorable concentration-time profiles with target exposures of therapeutic potential
  • Well tolerated with no safety signals of concern over entire dose range
    
• Company to advance INF904 into Phase II clinical development
• Company to host a conference call today, January 4, 2024 at 8:30 a.m. EST/14:30 CET

InflaRx will host a conference call today, January 4, 2024 at 8:30 a.m. EST (14:30 CET) to provide more details about the announced topline results of the MAD part of its Phase I study of INF904 in healthy human subjects. To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call. A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.

InflaRx’s management team will host investor and business meetings during JPM Week from January 8 to 11, 2024 in San Francisco, California.

https://www.globenewswire.com/news-release/2024/01/04/2803830/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Multiple-Ascending-Dose-MAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html